Trial reportMedical oncology (Northwood, London, England)2006
Efficacy and safety results with the combination therapy of arsenic trioxide, dexamethasone, and ascorbic acid in multiple myeloma patients: a phase 2 trial.
Trial report in Medical oncology (Northwood, London, England), 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Is there a role for oral or intravenous ascorbate (vitamin C) in treating patients with cancer? A systematic review.The oncologist · 2015Pooled it
- A phase II study of arsenic trioxide in patients with relapsed or refractory malignant lymphoma.Medical oncology (Northwood, London, England) · 2015Trial
- Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network study.Hematological oncology · 2009Trial
- High-dose vitamin C as a metabolic treatment of cancer: a new dimension in the era of adjuvant and intensive therapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Review
- High-Dose Vitamin C in Advanced-Stage Cancer Patients.Nutrients · 2021Review
- Intravenous vitamin C for reduction of cytokines storm in acute respiratory distress syndrome.PharmaNutrition · 2020Review
- Phase I study of high-dose ascorbic acid with mFOLFOX6 or FOLFIRI in patients with metastatic colorectal cancer or gastric cancer.BMC cancer · 2019Article
- Ascorbic Acid in Colon Cancer: From the Basic to the Clinical Applications.International journal of molecular sciences · 2018Review
- Systematic Review of Intravenous Ascorbate in Cancer Clinical Trials.Antioxidants (Basel, Switzerland) · 2018Review
- Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma.British journal of haematology · 2017Article
- Advances in Synergistic Combinations of Chinese Herbal Medicine for the Treatment of Cancer.Current cancer drug targets · 2016Review
- Arsenic trioxide-based therapy in relapsed/refractory multiple myeloma patients: a meta-analysis and systematic review.OncoTargets and therapy · 2014Review
- Arsenic trioxide inhibits the proliferation of myeloma cell line through notch signaling pathway.Cancer cell international · 2013Article
- Article
- Review
- Arsenic trioxide - An old drug rediscovered.Blood reviewsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSingle-agent arsenic trioxide has shown promising results in patients with relapsed or refractory multiple myeloma (MM). Because preclinical data suggested greater activity with dexamethasone and ascorbic acid, a phase 2 trial of the combination of arsenic trioxide, dexamethasone, and ascorbic acid in patients with relapsed or refractory MM was conducted.
methodsTwenty patients in whom no more than two previous therapies had failed were enrolled. The mean age was 62 yr, and 55% of the patients had refractory disease. The regimen consisted of 14- or 15-wk cycles, with the first cycle considered induction, followed by one or two consolidation cycles with a reduced steroid schedule and then a maintenance cycle in responding patients.
resultsThe overall response rate was 30%, with at least stable disease in 80% of patients. Median progression- free survival was 316 d in all patients and 584 d in those with a response. The regimen was well tolerated, with most adverse events being mild or moderate.
conclusionsThis study showed the clinical efficacy and tolerability of the combination of arsenic trioxide, dexamethasone, and ascorbic acid. Further study is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.